Scailyte participates @ swissnex san francisco DEMO DAY!

scailyte swissnex demo day

Striving to internationalize and network, Scailyte participates and pitches at the swissnex Demo Day. Scailyte will present its pioneering AI-based platform for biomarker discovery from single-cell and clinical data to enable precision diagnostics in oncology, immunology and women’s health. Scailyte’s forward-thinking team will explain how they plan to unlock clinically relevant insights which will improve patient outcomes.

Continue reading

Scailyte closed today their pre-series A financing

Scailyte closes pre-series A

Dynamic Meta widget allowed only for Posts listing source or in Post context

Scailyte closed their pre-series A financing round with CHF 3.7 million led by Swisscom Ventures, 4FO ventures, Hemex and Investiere.

Scailyte™ is delighted to welcome investiere as an additional investor just before closing the pre-series A financing round.™

Today, Scailyte closed their pre-series A financing round with CHF 3.7 million led by Swisscom Ventures, joined by 4FO ventures, a private investor, Hemex and Investiere. This pre-series A financing round will allow Scailyte to develop faster their assays in the rapid-emerging single-cell data technology field. The raised capital will be used to further build upon Scailyte’s biomarker and IVD pipeline and for the development of the first clinical applications using single-cell biomarkers.

Scailyte is honored to have investiere among their renowned investor base. The additional financing increases the opportunities for Scailyte to develop in-vitro diagnostics using single-cell technologies and their proprietary single-cell data analysis platform ScaiVision™.

“We are continuously developing and utilizing our data analytics platform ScaiVision™ for biomarker discovery from single-cell data” says Peter Nestorov, CEO of Scailyte AG. “The current version covers all aspects of processing, handling and interpreting single-cell proteomics data (mass and flow cytometry), as well as a core functionality for analysing single-cell transcriptomics data. This allows us to accelerate biomedical discovery and enable the next generation of precision diagnostics. With the support of strong partners like Swisscom Ventures, 4FO and HEMEX, we will continue to grow in the fast-emerging single-cell analysis field, enabling various clinical applications of single-cell data “.

“Scailyte has a strong product pipeline. It includes candidates for biomarkers for Endometriosis and CTCL with a market potential of several hundred million Francs for each of these diagnostics. Furthermore, Scailyte enjoys strong support in the medical expert community” says Susanne Schorsch, Investment Manager at investiere.

investiere provides exclusive access to start-up investments to qualified private and institutional investors. investiere is one of the most active startup investors in Switzerland, backed by business angels as well as ZKB with more than 90 investments.

Scailyte AG was founded in Luzern, Switzerland in July 2017. Scailyte is an ETH Zurich spin-off and is supported by Innosuisse (Swiss Innovation Agency). The company has gained recognition by winning several national and international start-ups competitions and is the beneficiary of significant research grants. Scailyte has a multi-disciplinary team with expertise in Cell biology, Genetics, Artificial Intelligence, Software development, Finance, Marketing and Sales. Scailyte discovers ultrasensitive biomarkers and develops in-vitro diagnostics using single-cell technologies and their proprietary single-cell data analysis platform ScaiVision™. ScaiVision™ offers best-in-class analysis of complex single-cell data to enhance biomedical research, pharmaceutical discovery, and precision diagnostics. Besides developing its own in vitro diagnostic (IVD) applications, Scailyte also offers its biomarker discovery services to companies aiming to complement and enrich their analysis by adding the single-cell perspective.

The ScaiVision™ biomarker discovery platform delivers best-in-class performance for supervised pattern recognition analysis of single-cell data. The performance and clinically relevant application of the core deep learning algorithm of ScaiVision have been validated in several scientific papers and have resulted in patent-pending diagnostic applications. For more information visit www.scailyte.com

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

Scailyte and Lexogen create a joint biomarker discovery workflow

Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solution

Read more

Recent News

Scailyte Quarterly Update June 2021

June 2021 Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Recent News

Michael Brenner, of Harvard Medical School, joins Scailyte as advisor

Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte announced today that Mich

Read more

Recent News

Acute respiratory distress syndrome comparative immune profiling

Acute respiratory distress syndrome (ARDS) is the main complication of coronavirus disease 2019 (COV

Read more

Recent News

Scailyte Quarterly Update April 2021

April 2021 Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Recent News

Scailyte and Geninus announce a strategic partnership

Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte and the global single-cel

Read more

Recent News

Scailyte and Volv Global announce strategic partnership

Two Artificial Intelligence (AI)-driven biomarker discovery companies Scailyte and Volv Global today

Read more

Recent News

Scailyte Quarterly Update January 2021

Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Recent News

01 /04

Scailyte and Lexogen create a joint biomarker discovery workflow

Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solution

Read more

Scailyte Quarterly Update June 2021

June 2021 Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Recent News

02 /04

Michael Brenner, of Harvard Medical School, joins Scailyte as advisor

Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte announced today that Mich

Read more

Acute respiratory distress syndrome comparative immune profiling

Acute respiratory distress syndrome (ARDS) is the main complication of coronavirus disease 2019 (COV

Read more

Recent News

03 /04

Scailyte Quarterly Update April 2021

April 2021 Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Scailyte and Geninus announce a strategic partnership

Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte and the global single-cel

Read more

Recent News

04 /04

Scailyte and Volv Global announce strategic partnership

Two Artificial Intelligence (AI)-driven biomarker discovery companies Scailyte and Volv Global today

Read more

Scailyte Quarterly Update January 2021

Quarterly update on Scailyte's progress towards its mission to save millions of lives.

Read more

Recent News